Shenqi Medical

Shenqi Medical is an innovative medical device enterprise that integrates research and development, production, and sales. Its product portfolio covers the fields of cardiovascular intervention, structural heart disease, peripheral vascular intervention, and neurovascular intervention. The company also has a joint venture, Beijing Hartkell Medical Technology Co., Ltd. ("Hartkell"), which is the first domestic enterprise to develop and produce ultrafiltration treatment equipment for heart failure in China. Shenqi Medical currently has two marketed products and 33 products under development, all of which are self-developed with comprehensive independent intellectual property rights. Among them, the swide® Qi Ji® drug-coated coronary balloon catheter was approved by the National Medical Products Administration for a Class III medical device registration certificate in December 2019, selected for the "Recommended Catalogue of Innovative Products in Shanghai (Second Batch) in 2020" in December 2020, recognized as one of the second batch of high-tech transformation projects in Shanghai in July 2021, and has now entered over 1,100 hospitals in China. The peripheral vascular intervention product SQ-WindRider® Qi Yi® detachable fiber-coated coil embolization system received the Class III medical device registration certificate from the National Medical Products Administration in January 2022. The SQ-Kyrin® Shenqi Qi Lin® transcatheter mitral valve clip and steerable guiding catheter entered the National Innovative Medical Device Registration Green Channel in August 2021.